Sign in →

Test ID F8IS Coagulation Factor VIII Inhibitor Screen, Plasma


Specimen Required


Only orderable as a reflex. For more information see:

8INHE / Factor VIII Inhibitor Evaluation, Plasma

ALUPP / Lupus Anticoagulant Profile, Plasma

ALBLD / Bleeding Diathesis Profile, Limited, Plasma

APROL / Prolonged Clot Time Profile, Plasma

AVWPR / von Willebrand Disease Profile, Plasma

 

For more information see Coagulation Guidelines for Specimen Handling and Processing.


Method Name

Only orderable as a reflex. For more information see:

8INHE / Factor VIII Inhibitor Evaluation, Plasma

ALUPP / Lupus Anticoagulant Profile, Plasma

ALBLD / Bleeding Diathesis Profile, Limited, Plasma

APROL / Prolonged Clot Time Profile, Plasma

AVWPR / von Willebrand Disease Profile, Plasma

 

Optical Clot-Based

Reporting Name

Coag Factor VIII Assay Inhib Scrn,P

Specimen Type

Plasma Na Cit

Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma Na Cit Frozen 14 days

Reference Values

Only orderable as a reflex. For more information see:

8INHE / Factor VIII Inhibitor Evaluation, Plasma

ALUPP / Lupus Anticoagulant Profile, Plasma

ALBLD / Bleeding Diathesis Profile, Limited, Plasma

APROL / Prolonged Clot Time Profile, Plasma

AVWPR / von Willebrand Disease Profile, Plasma

 

Negative

Day(s) Performed

Monday through Friday

Report Available

1 to 3 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

85335

LOINC Code Information

Test ID Test Order Name Order LOINC Value
F8IS Coag Factor VIII Assay Inhib Scrn,P 3206-0

 

Result ID Test Result Name Result LOINC Value
7289 Coag Factor VIII Assay Inhib Scrn,P 3206-0

Useful For

Detecting the presence of a specific factor inhibitor directed against coagulation factor VIII